By Editorial TeamAtrial fibrillation (AFib) is the most common arrhythmia we deal with, and it’s a total paradox. It dramatically bumps up the risk for stroke, but we often don’t find it until after the stroke happens. The condition can be completely silent, progressing for years without anyone knowing, which is why so many people are left vulnerable. AFib is so hard to diagnose because it’s often asymptomatic or comes and goes. A lot of people feel nothing at all. Others have symptoms like palpitations, fatigue, or shortness of breath that are so mild or infrequent they just brush them off as something else. This means when a patient comes in for a routine check-up and we run a standard ECG, which only lasts a few minutes, we’re likely to miss an episode entirely. The heart is probably in a normal sinus rhythm right then, giving everyone a false sense of security. What makes it even tougher is that even when people do have symptoms, they vary wildly. One person gets intense, fluttering feelings in their chest, while another just feels a bit off or gets winded more easily during exercise. With such a wide spectrum, it’s difficult for patients to recognize a problem and for clinicians to identify it without monitoring them for a longer period.
Bridging the Detection Gap with Extended Monitoring
Since AFib is so often intermittent, short-term diagnostic tests are basically a shot in the dark. This has pushed us toward using longer-duration or continuous cardiac monitoring to catch those fleeting, asymptomatic episodes that would otherwise be missed. The longer you monitor, the higher your chances of actually detecting the arrhythmia. For a long time, our main tools were ambulatory ECGs like Holter monitors (which you’d wear for 24-48 hours) and event recorders. But they have their own problems. A Holter can still miss AFib if an episode doesn’t pop up in that one- or two-day window. Event recorders are even more limited because they require the patient to actually feel something and press a button, which is totally useless for asymptomatic AFib.
The mSToPS Study: A Landmark in Silent AFib Detection
The mSToPS (mHealth Screening to Prevent Strokes) study, led by Scripps Research, really showed how effective extended monitoring is. It was designed to see if long-term, continuous monitoring could find previously undiagnosed AFib in people who were considered at moderate risk but had no history of the condition mSToPS study primary publication. The study used the Zio XT, an FDA-cleared wearable patch from iRhythm Technologies that provides continuous ECG monitoring for up to 14 days. This much longer window gave them a huge amount of cardiac rhythm data compared to a quick in-office ECG or a standard Holter. The main goal was simple: find AFib that would have otherwise gone undetected. The results were significant. The group wearing the patches had a much, much higher rate of AFib detection compared to the control group that just got the usual care. This gave us real-world proof that extended, continuous monitoring works for finding silent or paroxysmal AFib. Finding these cases before a stroke happens is the whole point of preventive medicine. This research showed exactly how longer monitoring helps close the detection gap. iRhythm SEC filings referencing mSToPS study
The Broader Field of AI in Cardiac Monitoring
The success of research like mSToPS set the stage for more work in AI-based cardiac monitoring and diagnostics. The study’s core principle, that you need prolonged data acquisition to catch intermittent events, is perfect for cardiovascular AI. We’re seeing more and more AI platforms being built to crunch the massive datasets that come from these continuous monitors. These platforms are designed to spot subtle patterns and anomalies in ECG data that a human might miss, which should make AFib detection faster and more accurate. The cardiac AI market is expanding fast. It was estimated at USD 3.44 billion in 2026 and is projected to hit USD 49.16 billion by 2035, growing at a CAGR of 34.38% from 2026 to 2035. Companies like iRhythm Technologies are continuing to build on this, with FDA-cleared devices like their Zio monitor and the ZEUS System for the Zio Watch, which uses AI algorithms to get better arrhythmia detection. iRhythm’s own financials show the growth, with a 20.1% year-over-year revenue jump in Q2 2026, and they’re expanding through acquisitions like VitalConnect to offer a complete cardiac monitoring platform. AI’s function here is to detect AFib, stratify patient risk, and predict future cardiac events. By training on huge datasets, these AI models learn to flag individuals at higher risk for developing AFib or having a complication, so we can intervene sooner.
The Path Forward: From Detection to Prevention
To stop AFib from causing a stroke, you have to find it first. Because the arrhythmia is silent and intermittent, we have to move away from episodic, point-in-time diagnostics and embrace continuous, prolonged monitoring. The mSToPS study gives us clear evidence that this is the right approach, showing how wearable ECG monitoring can uncover previously hidden AFib in at-risk people. As AI gets better, integrating it into cardiac monitoring will only improve our ability to detect AFib earlier and with more precision. This is how we can transform stroke prevention, moving toward a reality where we identify these silent threats before they cause a life-changing event. Review article on AI in AFib detection
Frequently Asked Questions
What is AFib and why is it a concern for stroke risk?
AFib, or Atrial Fibrillation, is the most common sustained cardiac arrhythmia. It significantly increases the risk of stroke and other adverse outcomes. The concern arises because AFib often goes undetected, silently progressing until a more severe event like a stroke occurs.
Why is AFib so difficult to detect?
AFib is difficult to detect because it can be asymptomatic or intermittent. Many individuals experience no symptoms, or their symptoms are subtle or sporadic, making them easy to dismiss. Standard, short-duration diagnostic tools like routine ECGs often miss AFib episodes if the heart is in normal rhythm at the time of examination.
How can doctors better detect AFib, especially silent or intermittent cases?
Doctors can better detect AFib through longer-duration or continuous cardiac monitoring approaches. Technologies like Holter monitors (24-48 hours) and event recorders aim to capture fleeting or asymptomatic AFib episodes that short-duration tests might miss. The mSToPS study demonstrated that extended continuous monitoring, such as with a 14-day wearable patch, significantly increases AFib detection rates in moderate-risk individuals.
What is the mSToPS study and what did it find about AFib detection?
The mSToPS (mHealth Screening to Prevent Strokes) study was a landmark study that evaluated the effectiveness of long-term, continuous monitoring for detecting silent, previously undiagnosed AFib in moderate-risk individuals. It found a significantly higher rate of AFib detection in the group that underwent prolonged monitoring compared to a control group receiving usual care. This demonstrated that extended monitoring is highly effective in identifying asymptomatic or paroxysmal AFib.
